Cargando…

Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment

OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological...

Descripción completa

Detalles Bibliográficos
Autores principales: Elvstam, Olof, Medstrand, Patrik, Yilmaz, Aylin, Isberg, Per-Erik, Gisslén, Magnus, Björkman, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500364/
https://www.ncbi.nlm.nih.gov/pubmed/28683128
http://dx.doi.org/10.1371/journal.pone.0180761
_version_ 1783248618722951168
author Elvstam, Olof
Medstrand, Patrik
Yilmaz, Aylin
Isberg, Per-Erik
Gisslén, Magnus
Björkman, Per
author_facet Elvstam, Olof
Medstrand, Patrik
Yilmaz, Aylin
Isberg, Per-Erik
Gisslén, Magnus
Björkman, Per
author_sort Elvstam, Olof
collection PubMed
description OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological failure and/or all-cause mortality among Swedish patients receiving ART. METHODS: HIV-infected patients from two Swedish HIV centers were identified from the nationwide register InfCare HIV. Subjects aged ≥15 years with triple agent ART were included at 12 months after treatment initiation if ≥2 following viral load measurements were available. Patients with 2 consecutive HIV RNA values ≥1000 copies/mL at this time point were excluded. Participants were stratified into four categories depending on viremia profiles: permanently suppressed viremia (<50 copies/mL), LLV 50–199 copies/mL, LLV 200–999 copies/mL and viremia ≥1000 copies/mL. Association between all four viremia categories and all-cause death was calculated using survival analysis with viremia as a time-varying covariate, so that patients could change viremia category during follow-up. Association between the three lower categories and virological failure (≥2 consecutive measurements ≥1000 copies/mL) was calculated in a similar manner. RESULTS: LLV 50–199 copies/mL was recorded in 70/1015 patients (6.9%) and LLV 200–999 copies/mL in 89 (8.8%) during 7812 person-years of follow-up (median 6.5 years). LLV 200–999 copies/mL was associated with virological failure (adjusted hazard ratio 3.14 [95% confidence interval 1.41–7.03, p<0.01]), whereas LLV 50–199 copies/mL was not (1.01 [0.34–4.31, p = 0.99]; median follow-up 4.5 years). LLV 200–999 copies/mL had an adjusted mortality hazard ratio of 2.29 (0.98–5.32, p = 0.05) and LLV 50–199 copies/mL of 2.19 (0.90–5.37, p = 0.09). CONCLUSIONS: In this Swedish cohort followed during ART for a median of 4.5 years, LLV 200–999 copies/mL was independently associated with virological failure. Patients with LLV had higher rates of all-cause mortality, although not statistically significant in multivariate analysis.
format Online
Article
Text
id pubmed-5500364
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55003642017-07-11 Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment Elvstam, Olof Medstrand, Patrik Yilmaz, Aylin Isberg, Per-Erik Gisslén, Magnus Björkman, Per PLoS One Research Article OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological failure and/or all-cause mortality among Swedish patients receiving ART. METHODS: HIV-infected patients from two Swedish HIV centers were identified from the nationwide register InfCare HIV. Subjects aged ≥15 years with triple agent ART were included at 12 months after treatment initiation if ≥2 following viral load measurements were available. Patients with 2 consecutive HIV RNA values ≥1000 copies/mL at this time point were excluded. Participants were stratified into four categories depending on viremia profiles: permanently suppressed viremia (<50 copies/mL), LLV 50–199 copies/mL, LLV 200–999 copies/mL and viremia ≥1000 copies/mL. Association between all four viremia categories and all-cause death was calculated using survival analysis with viremia as a time-varying covariate, so that patients could change viremia category during follow-up. Association between the three lower categories and virological failure (≥2 consecutive measurements ≥1000 copies/mL) was calculated in a similar manner. RESULTS: LLV 50–199 copies/mL was recorded in 70/1015 patients (6.9%) and LLV 200–999 copies/mL in 89 (8.8%) during 7812 person-years of follow-up (median 6.5 years). LLV 200–999 copies/mL was associated with virological failure (adjusted hazard ratio 3.14 [95% confidence interval 1.41–7.03, p<0.01]), whereas LLV 50–199 copies/mL was not (1.01 [0.34–4.31, p = 0.99]; median follow-up 4.5 years). LLV 200–999 copies/mL had an adjusted mortality hazard ratio of 2.29 (0.98–5.32, p = 0.05) and LLV 50–199 copies/mL of 2.19 (0.90–5.37, p = 0.09). CONCLUSIONS: In this Swedish cohort followed during ART for a median of 4.5 years, LLV 200–999 copies/mL was independently associated with virological failure. Patients with LLV had higher rates of all-cause mortality, although not statistically significant in multivariate analysis. Public Library of Science 2017-07-06 /pmc/articles/PMC5500364/ /pubmed/28683128 http://dx.doi.org/10.1371/journal.pone.0180761 Text en © 2017 Elvstam et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Elvstam, Olof
Medstrand, Patrik
Yilmaz, Aylin
Isberg, Per-Erik
Gisslén, Magnus
Björkman, Per
Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
title Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
title_full Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
title_fullStr Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
title_full_unstemmed Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
title_short Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
title_sort virological failure and all-cause mortality in hiv-positive adults with low-level viremia during antiretroviral treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500364/
https://www.ncbi.nlm.nih.gov/pubmed/28683128
http://dx.doi.org/10.1371/journal.pone.0180761
work_keys_str_mv AT elvstamolof virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment
AT medstrandpatrik virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment
AT yilmazaylin virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment
AT isbergpererik virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment
AT gisslenmagnus virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment
AT bjorkmanper virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment